Ospamox® (Tablets, Capsules, Powder) Instructions for Use
ATC Code
J01CA04 (Amoxicillin)
Active Substance
Amoxicillin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Broad-spectrum penicillin antibiotic, destroyed by penicillinase
Pharmacotherapeutic Group
Antibiotic, semi-synthetic penicillin
Pharmacological Action
An antibiotic from the group of semi-synthetic penicillins with a broad spectrum of action. It is a 4-hydroxy analog of ampicillin. It has a bactericidal effect. Active against aerobic gram-positive bacteria: Staphylococcus spp. (except for strains producing penicillinase), Streptococcus spp.; aerobic gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli, Shigella spp., Salmonella spp., Klebsiella spp.
Microorganisms producing penicillinase are resistant to amoxicillin.
In combination with metronidazole, it shows activity against Helicobacter pylori. It is believed that Amoxicillin inhibits the development of resistance of Helicobacter pylori to metronidazole.
There is cross-resistance between amoxicillin and ampicillin.
The spectrum of antibacterial action expands with the simultaneous use of amoxicillin and the beta-lactamase inhibitor clavulanic acid. In this combination, the activity of amoxicillin against Bacteroides spp., Legionella spp., Nocardia spp., Pseudomonas (Burkholderia) pseudomallei increases. However, Pseudomonas aeruginosa, Serratia marcescens and many other gram-negative bacteria remain resistant.
Pharmacokinetics
When taken orally, Amoxicillin is rapidly and completely absorbed from the gastrointestinal tract, not destroyed in the acidic environment of the stomach. Cmax of amoxicillin in blood plasma is reached in 1-2 hours. When the dose is doubled, the concentration also doubles. The presence of food in the stomach does not reduce overall absorption. Similar concentrations of amoxicillin in the blood are achieved with IV, IM administration and oral intake.
The binding of amoxicillin to plasma proteins is about 20%.
It is widely distributed in body tissues and fluids. High concentrations of amoxicillin in the liver have been reported.
T1/2 from plasma is 1-1.5 hours. About 60% of the orally administered dose is excreted unchanged in the urine by glomerular filtration and tubular secretion; at a dose of 250 mg, the concentration of amoxicillin in the urine is more than 300 mcg/ml. Some amount of amoxicillin is detected in feces.
In newborns and elderly individuals, T1/2 may be longer.
In renal failure, T1/2 can be 7-20 hours.
Amoxicillin penetrates the blood-brain barrier in small amounts when the meninges are inflamed.
Amoxicillin is removed by hemodialysis.
Indications
For use as monotherapy and in combination with clavulanic acid: infectious and inflammatory diseases caused by susceptible microorganisms, including bronchitis, pneumonia, tonsillitis, pyelonephritis, urethritis, gastrointestinal infections, gynecological infections, infectious diseases of the skin and soft tissues, listeriosis, leptospirosis, gonorrhea.
For use in combination with metronidazole: chronic gastritis in the acute phase, gastric and duodenal ulcer in the acute phase, associated with Helicobacter pylori.
ICD codes
| ICD-10 code | Indication |
| A27 | Leptospirosis |
| A32 | Listeriosis |
| A54 | Gonococcal infection |
| B98.0 | Helicobacter pylori as the cause of diseases classified elsewhere |
| J03 | Acute tonsillitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J35.0 | Chronic tonsillitis |
| J42 | Unspecified chronic bronchitis |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| K27 | Peptic ulcer |
| K29 | Gastritis and duodenitis |
| K65.0 | Acute peritonitis (including abscess) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A7Z | Gonococcal infection, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1B91 | Leptospirosis |
| 1C1A.Z | Listeriosis, unspecified |
| 1C44 | Non-pyogenic bacterial infections of skin |
| CA03.Z | Acute tonsillitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA60.Z | Gastric ulcer, unspecified |
| DA61 | Peptic ulcer of unspecified site |
| DA63.Z | Duodenal ulcer, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| DC50.0 | Primary peritonitis |
| DC50.2 | Peritoneal abscess |
| DC50.Z | Peritonitis, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| XN3DY | Helicobacter pylori (H. pylori) |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets, Capsules, Powder
Individual. For oral administration, a single dose for adults and children over 10 years of age (with a body weight over 40 kg) is 250-500 mg, in severe cases of the disease – up to 1 g. For children aged 5-10 years, a single dose is 250 mg; for children aged 2 to 5 years – 125 mg. The interval between doses is 8 hours. For children with a body weight less than 40 kg, the daily dose depending on the indications and clinical situation can be 20-100 mg/kg in 2-3 doses.
For the treatment of acute uncomplicated gonorrhea – 3 g once (in combination with probenecid). In patients with impaired renal function with a CC of 10-40 ml/min, the interval between doses should be increased to 12 hours; with a CC less than 10 ml/min, the interval between doses should be 24 hours.
For parenteral use in adults, IM – 1 g 2 times/day, IV (with normal renal function) – 2-12 g/day. For children, IM – 50 mg/kg/day, single dose – 500 mg, frequency of administration – 2 times/day; IV – 100-200 mg/kg/day. For patients with impaired renal function, the dose and interval between administrations must be adjusted according to CC values.
Adverse Reactions
From the digestive system often – nausea, diarrhea; infrequently – vomiting; rarely – dyspepsia, epigastric pain; very rarely – antibiotic-associated colitis (including pseudomembranous and hemorrhagic colitis), diarrhea with blood, black discoloration of the tongue; frequency unknown – taste change, stomatitis, glossitis.
From the nervous system often – drowsiness, headache; rarely: nervousness, agitation, anxiety, ataxia, behavior change, peripheral neuropathy, restlessness, sleep disorder, depression, paresthesia, tremor, confusion; very rarely – hyperkinesia, dizziness, seizures, hyperesthesia, impairment of vision, smell and tactile sensitivity, hallucinations, aseptic meningitis.
From the cardiovascular system often – tachycardia, phlebitis; rarely – decreased BP; very rarely – QT interval prolongation.
From the liver and biliary tract often – increased serum bilirubin concentration; very rarely – hepatitis, cholestatic jaundice, moderate increase in ALT, AST, ALP, GGT activity, acute liver failure.
From the skin and subcutaneous tissues: often – skin rash; infrequently – urticaria, skin itching; very rarely – photosensitivity, edema of the skin and mucous membranes, toxic epidermal necrolysis (Lyell’s syndrome), Stevens-Johnson syndrome, erythema multiforme, bullous exfoliative dermatitis, acute generalized exanthematous pustulosis and drug rash with eosinophilia and systemic symptoms (DRESS syndrome).
Infectious and parasitic diseases rarely – superinfection (especially in patients with chronic diseases or reduced body resistance); very rarely – candidiasis of the skin and mucous membranes.
From the blood and lymphatic system very rarely – reversible leukopenia (including severe neutropenia and agranulocytosis), reversible thrombocytopenia, hemolytic anemia, increased blood clotting time, increased prothrombin time; frequency unknown – eosinophilia.
From the immune system rarely – serum sickness-like reactions; very rarely – severe allergic reactions, including angioedema, anaphylactic shock, serum sickness and allergic vasculitis; frequency unknown – Jarisch-Herxheimer reaction, allergic acute coronary syndrome (Kounis syndrome).
From the endocrine system rarely – anorexia; very rarely – hypoglycemia, especially in patients with diabetes mellitus.
From the respiratory system rarely – bronchospasm, dyspnea; very rarely – allergic pneumonitis.
From the musculoskeletal system: rarely – arthralgia, myalgia, tendon disorders including tendinitis; very rarely: tendon rupture (bilateral possible and after 48 hours of treatment initiation), muscle weakness, rhabdomyolysis.
From the urinary system rarely – increased serum creatinine concentration; very rarely – interstitial nephritis, crystalluria.
General disorders general weakness; very rarely – increased body temperature.
Contraindications
Infectious mononucleosis, lymphocytic leukemia, severe gastrointestinal infections accompanied by diarrhea or vomiting, respiratory viral infections, allergic diathesis, bronchial asthma, hay fever, hypersensitivity to penicillins and/or cephalosporins.
For use in combination with metronidazole: diseases of the nervous system; hematopoiesis disorders, lymphocytic leukemia, infectious mononucleosis; hypersensitivity to nitroimidazole derivatives.
For use in combination with clavulanic acid: history of liver function disorders and jaundice associated with the use of amoxicillin in combination with clavulanic acid.
Use in Pregnancy and Lactation
Amoxicillin crosses the placental barrier and is excreted in small amounts in breast milk.
If it is necessary to use amoxicillin during pregnancy, the expected benefit of therapy for the mother and the potential risk to the fetus should be carefully weighed.
Use Amoxicillin with caution during lactation (breastfeeding).
Use in Hepatic Impairment
Amoxicillin in combination with metronidazole should not be used in liver diseases.
Use in Renal Impairment
In patients with impaired renal function, the dose and interval between administrations must be adjusted according to CC values.
Pediatric Use
Use in children is possible according to the dosage regimen.
Amoxicillin in combination with metronidazole is not recommended for use in patients under 18 years of age.
Special Precautions
Use with caution in patients prone to allergic reactions.
Amoxicillin in combination with metronidazole is not recommended for use in patients under 18 years of age; should not be used in liver diseases.
During combination therapy with metronidazole, alcohol consumption is not recommended.
Drug Interactions
Amoxicillin may reduce the effectiveness of oral contraceptives.
With simultaneous use of amoxicillin with bactericidal antibiotics (including aminoglycosides, cephalosporins, cycloserine, vancomycin, rifampicin), synergy is manifested; with bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines, sulfonamides) – antagonism.
Amoxicillin enhances the effect of indirect anticoagulants by suppressing the intestinal microflora, reduces the synthesis of vitamin K and the prothrombin index.
Amoxicillin reduces the effect of drugs that are metabolized to form PABA.
Probenecid, diuretics, allopurinol, phenylbutazone, NSAIDs reduce the tubular secretion of amoxicillin, which may be accompanied by an increase in its concentration in the blood plasma.
Antacids, glucosamine, laxatives, aminoglycosides slow down and reduce, and ascorbic acid increases the absorption of amoxicillin.
With combined use of amoxicillin and clavulanic acid, the pharmacokinetics of both components do not change.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Dispersible tablets 500 mg: 10, 12, 14, 16, 20, 30, or 100 pcs.
Dispersible tablets 750 mg: 14, 16, 20, or 30 pcs.
Dispersible tablets 1000 mg: 12, 14, 16, 20 or 30 pcs.
Marketing Authorization Holder
Sandoz, d.d. (Slovenia)
Manufactured By
Sandoz, GmbH (Austria)
Dosage Forms
| Ospamox® | Dispersible tablets 500 mg: 10, 12, 14, 16, 20, 30, or 100 pcs. | |
| Dispersible tablets 750 mg: 14, 16, 20, or 30 pcs. | ||
| Dispersible tablets 1000 mg: 12, 14, 16, 20 or 30 pcs. |
Dosage Form, Packaging, and Composition
Dispersible tablets from white to yellowish-white, oblong, biconvex, with a score on both sides, approximately 8 mm wide and approximately 18 mm long; on cross-section – from white to yellowish-white.
| 1 tab. | |
| Amoxicillin trihydrate | 547 mg, |
| Equivalent to amoxicillin content | 500 mg |
Excipients : peach-apricot flavor – 1.4 mg, orange flavor – 2 mg, magnesium stearate – 2.2 mg, aspartame – 2.4 mg, croscarmellose sodium – 10 mg, mannitol – 12 mg, talc – 15 mg, colloidal anhydrous silicon dioxide – 30 mg, microcrystalline cellulose – 51 mg.
Coating composition aspartame – 0.23 mg, mannitol – 2.45 mg, maltodextrin – 2.45 mg, starch – 2.45 mg, titanium dioxide – 2.57 mg, talc – 3.85 mg.
6 pcs. – blisters (2) – cardboard packs.
7 pcs. – blisters (2) – cardboard packs.
8 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (10) – cardboard packs.
Dispersible tablets from white to yellowish-white, oblong, biconvex, with a score on both sides, approximately 9 mm wide and approximately 20 mm long; on cross-section – from white to yellowish-white.
| 1 tab. | |
| Amoxicillin trihydrate | 861 mg, |
| Equivalent to amoxicillin content | 750 mg |
Excipients : peach-apricot flavor – 2.1 mg, orange flavor – 3 mg, magnesium stearate – 3.3 mg, aspartame – 3.6 mg, croscarmellose sodium – 15 mg, mannitol – 18 mg, talc – 22.5 mg, colloidal anhydrous silicon dioxide – 45 mg, microcrystalline cellulose – 76.5 mg.
Shell composition aspartame – 0.3 mg, mannitol – 3.5 mg, maltodextrin – 3.5 mg, starch – 3.5 mg, titanium dioxide – 3.7 mg, talc – 5.5 mg.
7 pcs. – blisters (2) – carton packs.
8 pcs. – blisters (2) – carton packs.
10 pcs. – blisters (2) – carton packs.
10 pcs. – blisters (3) – carton packs.
Dispersible tablets from white to yellowish-white, oblong, biconvex, with a score on both sides, approximately 10 mm wide and approximately 22 mm long; on cross-section – from white to yellowish-white.
| 1 tab. | |
| Amoxicillin trihydrate | 1148 mg, |
| Equivalent to amoxicillin content | 1000 mg |
Excipients : peach-apricot flavor – 2.8 mg, orange flavor – 4 mg, magnesium stearate – 4.4 mg, aspartame – 4.8 mg, croscarmellose sodium – 20 mg, mannitol – 24 mg, talc – 30 mg, colloidal anhydrous silicon dioxide – 60 mg, microcrystalline cellulose – 102 mg.
Shell composition aspartame – 0.4 mg, mannitol – 4.2 mg, maltodextrin – 4.2 mg, starch – 4.2 mg, titanium dioxide – 4.4 mg, talc – 6.6 mg.
6 pcs. – blisters (2) – carton packs.
7 pcs. – blisters (2) – carton packs.
8 pcs. – blisters (2) – carton packs.
10 pcs. – blisters (2) – carton packs.
10 pcs. – blisters (3) – carton packs.
Powder for the preparation of oral suspension 125 mg/5 ml: bottle 5.1 g or 8.5 g incl. with a measuring spoon
Marketing Authorization Holder
Sandoz, GmbH (Austria)
Dosage Form
| Ospamox® | Powder for the preparation of oral suspension 125 mg/5 ml: bottle 5.1 g or 8.5 g incl. with a measuring spoon |
Dosage Form, Packaging, and Composition
Powder for the preparation of oral suspension white or white with a yellowish tint, with a characteristic fruity odor; prepared suspension is white or white with a yellowish tint, with a characteristic fruity odor, bittersweet taste.
| 5 ml of prepared susp. | |
| Amoxicillin trihydrate | 146.4 mg, |
| Equivalent to amoxicillin content | 125 mg |
Excipients : powdered lemon flavor – 1.8 mg, powdered peach-apricot flavor – 4.3 mg, anhydrous citric acid – 6 mg, sodium benzoate – 7.1 mg, aspartame – 8.5 mg, talc – 8.5 mg, anhydrous trisodium citrate – 19.2 mg, powdered orange flavor – 20 mg, guar galactomannan – 25 mg, precipitated silicon dioxide – 325.5 mg.
5.1 g – dark glass bottles (1) in a set with a measuring spoon – carton packs.
8.5 g – dark glass bottles (1) in a set with a measuring spoon – carton packs.
Powder for preparation of oral suspension 250 mg/5 ml: bottle 6.6 g or 11 g in set with measuring spoon
Marketing Authorization Holder
Sandoz, GmbH (Austria)
Dosage Form
| Ospamox® | Powder for preparation of oral suspension 250 mg/5 ml: bottle 6.6 g or 11 g in set with measuring spoon |
Dosage Form, Packaging, and Composition
Powder for the preparation of oral suspension white or white with a yellowish tint, with a characteristic fruity odor; prepared suspension is white or white with a yellowish tint, with a characteristic fruity odor, bittersweet taste.
| 5 ml of prepared susp. | |
| Amoxicillin trihydrate | 287 mg, |
| Equivalent to amoxicillin content | 250 mg |
Excipients : powdered lemon flavor – 1.8 mg, powdered peach-apricot flavor – 4.3 mg, anhydrous citric acid – 6 mg, sodium benzoate – 7.1 mg, aspartame – 8.5 mg, talc – 8.5 mg, anhydrous trisodium citrate – 19.2 mg, powdered orange flavor – 20 mg, guar galactomannan – 25 mg, precipitated silicon dioxide – 325.5 mg.
6.6 g – dark glass bottles (1) in a set with a measuring spoon – carton packs.
11 g – dark glass bottles (1) in a set with a measuring spoon – carton packs.
Powder for the preparation of oral suspension 500 mg/5 ml: fl. 12 g or 20 g incl. with measuring spoon
Marketing Authorization Holder
Sandoz, GmbH (Austria)
Dosage Form
| Ospamox® | Powder for the preparation of oral suspension 500 mg/5 ml: fl. 12 g or 20 g incl. with measuring spoon |
Dosage Form, Packaging, and Composition
Powder for the preparation of oral suspension white or white with a yellowish tint, with a characteristic fruity odor; prepared suspension is white or white with a yellowish tint, with a characteristic fruity odor, bittersweet taste.
| 5 ml of prepared susp. | |
| Amoxicillin trihydrate | 574.1 mg, |
| Equivalent to amoxicillin content | 500 mg |
Excipients : powdered lemon flavor – 1.8 mg, powdered peach-apricot flavor – 4.3 mg, anhydrous citric acid – 6 mg, sodium benzoate – 7.1 mg, aspartame – 8.5 mg, talc – 8.5 mg, anhydrous trisodium citrate – 19.2 mg, powdered orange flavor – 20 mg, guar galactomannan – 25 mg, precipitated silicon dioxide – 325.5 mg.
12 g – dark glass bottles (1) in a set with a measuring spoon – carton packs.
20 g – dark glass bottles (1) in a set with a measuring spoon – carton packs.
Capsules 250 mg: 1000 pcs.
Marketing Authorization Holder
Sandoz, GmbH (Austria)
Dosage Form
| Ospamox® | Capsules 250 mg: 1000 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard gelatin size No. 2, opaque, yellow; capsule contents – powder from white to cream color.
| 1 caps. | |
| Amoxicillin trihydrate | 287 mg, |
| Equivalent to amoxicillin content | 250 mg |
Excipients : magnesium stearate, microcrystalline cellulose.
Shell composition titanium dioxide, gelatin, yellow iron oxide.
10 pcs. – blisters (100) – carton boxes.
Film-coated tablets, 500 mg: 12 pcs.
Marketing Authorization Holder
Sandoz, GmbH (Austria)
Dosage Form
| Ospamox® | Film-coated tablets, 500 mg: 12 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets from white to slightly yellowish, oblong, biconvex, with score lines on both sides.
| 1 tab. | |
| Amoxicillin trihydrate | 574 mg, |
| Equivalent to Amoxicillin content | 500 mg |
Excipients : magnesium stearate, povidone, sodium starch glycolate, microcrystalline cellulose.
Shell composition titanium dioxide, talc, hypromellose.
12 pcs. – blisters (1) – carton packs.
Tablets, coated, 1 g: 12 pcs.
Marketing Authorization Holder
Sandoz, GmbH (Austria)
Dosage Form
| Ospamox® | Tablets, coated, 1 g: 12 pcs. |
Dosage Form, Packaging, and Composition
Coated tablets from white to slightly yellowish, oval, biconvex, with score lines on both sides.
| 1 tab. | |
| Amoxicillin trihydrate | 1.148 g, |
| Equivalent to amoxicillin content | 1 g |
Excipients : magnesium stearate, povidone, sodium starch glycolate, microcrystalline cellulose.
Shell composition titanium dioxide, talc, hypromellose.
6 pcs. – blisters (2) – carton packs.
Ingavirin capsules 90mg, 10pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, lotion solution for external use spray 100ml
Actovegin pills 200mg, 50pcs
Arbidol, capsules 100mg, 40pcs 